

Eman El-Ahwany (PhD) is a professor of Immunology, Immunology and Drug Evaluation Department, Theodor Bilharz Research Institute (TBRI). She graduated from Faculty of Science, Cairo University in 1991. She received her PhD in immunology in 2001. She worked as teaching assistant and faculty part-time in the Biology Department, the American University in Cairo (1999-2014). She is a member in the TBRI technical office and the TBRI Internal Research Projects Committee since 2011. She is a member in the European Association of Liver Diseases (EASL). Her field of interest is MicroRNAs and the epigenetic changes as non-invasive diagnostic and therapeutic tools in HCV-induced liver fibrosis and HCC. She has shared and worked as participant, Co-PI and PI in 20 research projects sponsored by international and national agencies, published 35 research articles in peer reviewed international journals, presented several abstracts in 30 International conferences and supervised 15 M.Sc. and PhD thesis. She is the coordinator of the MOU between TBRI and Country of Basque University in Spain (2016). She got two post doctor fellowships in Germany (2007) and France (2014). She has been awarded the TBRI excellence award in 2014.

List of most relevant recent publications

1. El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A and El- Bassiouni N (2006). Immunohistochemical expression of CD95 (Fas), c-myc, and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. *APMIS*, **114**: 420-427.
2. El-Bassiouny A, Zoheiry M, **El-Ahwany E**, Salah F, Nosseir M, Omran Z, Atta R, El-Bassiouny N (2008). Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. *MedGenMed*, **10 (6)**: 130-148.
3. Azza El Bassiouny, Samah Abo El-Hassan, Mona Moussa, **Eman El-Ahwany**, Eman Helal, Alaa Taha, Manal Kamel and Nora El-Bassiouni (2009). Down-Regulation of Intrahepatic CD16⁺ and CD56⁺ Immune Cells in Chronic Hepatitis C Virus Infection and HCV-related Hepatocellular Carcinoma. *Archives of Medical Science*, **5, 3**: 321-328.
4. El-Bassiouny AI, **El-Ahwany EG**, Abou-Shousha TS, Moussa MM, El- Bassiouni NI, Maher KM, Galli AY, Youssef MM and Zada SK (2009). Hepatic mRNA Expression of Histone (H3): An early predictor of tumorigenic changes in chronic hepatitis C. *Archives of Medical Science*, **5(4)**: 506-512.
5. Zakaria S, Youssef M, Moussa M, Akl M, **El-Ahwany E**, El-Raziky M, Mostafa O, Helmy AH and El-Hindawi A (2010). Value of alpha-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection. *Archives of Medical Sciences*, **6 (3)**: 356-365.
6. Amer M, Elhefnawi M, **El-Ahwany E**, Awad AF, Gawad NA, Zada S, Tawab FM (2014). Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. *Tumour Biol.*, **35 (11)**:11301-9.
7. Mona MK Zoheiry, Shaimaa AA Hasan, **Eman El-Ahwany**, Faten M Nagy, Hoda Abu Taleb, Mona Nosseir, Mona Magdi, Safa Meshaal, Mahmoud El-Ansari, Inas Raafat (2015). Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, cirrhosis and Hepatocellular Carcinoma. *Electron Physician Journal*, **7(8)**:1626-37.
8. **Eman El-Ahwany**, Faten Nagy, Mona Zoheiry, Mohamed Shemis, Mona Nosseir, Hoda Abu Taleb, Maged ElGhannam, Mohamed El-Talkawy, Rafaat Atta, Suher Zada (2016). Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis. *Electron Physician Journal*, **8(1)**:1804-10.